Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02517385 | Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases | PHASE3 | COMPLETED | 147 | — | — | Aug 1, 2015 | Jun 1, 2016 | Jul 4, 2016 | 1 | Russia |
| Arm | Type | Description |
|---|---|---|
| Phosphatidylcholine paste | EXPERIMENTAL | One dose of phosphatidylcholine paste 600 mg given orally 3 times a day at Days 0, 28, 56, and 84 |
| Name | Type | Description |
|---|---|---|
| Phosphatidylcholine | DRUG | Pharmaceutical form:Paste Route of administration: Oral |
Inclusion criteria: * Males and females ≥18 years of age and less than 66 years old. * Patients with gastrointestinal symptoms (fatigue, abdominal pain/discomfort, early satiety, fullness discomfort after meal, nausea/vomiting, belching/abdominal distension, at least one rated as "Moderate Problem"...